Literature DB >> 14651540

Tolmetin and salicylate therapy in acute rheumatic fever: Comparison of clinical efficacy and side-effects.

Selmin Karademir1, Deniz Oğuz, Filiz Senocak, Burhan Ocal, Cemşit Karakurt, Feryal Cabuk.   

Abstract

BACKGROUND: The arthritis of rheumatic fever is very responsive to treatment with salicylates, but there are many adverse reactions, especially hepatotoxicity, due to aspirin (acetylsalicylic acid) therapy. These side-effects change the course and duration of rheumatic fever. Other non-steroidal anti-inflammatory drugs may be equally effective, although no reports are available.
METHODS: We studied 72 patients with rheumatic fever who were admitted to Dr Sami Ulus Children's Hospital between 1995 and 1999. Twenty patients with arthritis were treated with tolmetin (25 mg/kg per day; group I) and 52 patients with arthritis and/or mild carditis were put on aspirin therapy (75-100 mg/kg per day) for 4-6 weeks (group II). Arthritis had disappeared at the same time in both the aspirin and tolmetin groups (P = 0.675).
RESULTS: The erythrocyte sedimentation rates of patients upon admission, at the first week and at the end of therapy were not different in the two groups (P > 0.05). No adverse effect of tolmetin therapy was observed, whereas side-effects of salicylate were observed in 19 patients (36.5%) in the aspirin group. Hepatotoxicity, gastric irritation and salicylism were found in 16, four and three patients, respectively. Renal toxicity and Reye syndrome were not demonstrated. Because of these side-effects of aspirin, therapy had to be stopped for 10-20 days and the duration of hospitalization in this group was lengthened unnecessarily.
CONCLUSION: Tolmetin was safe and effective treatment for arthritic rheumatic fever patients without carditis. Tolmetin can be used particularly in patients who cannot tolerate aspirin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14651540     DOI: 10.1111/j.1442-200x.2003.01801.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  2 in total

1.  Use of anti-inflammatory analgesics in sickle-cell disease.

Authors:  J Han; S L Saraf; J P Lash; V R Gordeuk
Journal:  J Clin Pharm Ther       Date:  2017-07-10       Impact factor: 2.512

2.  Effect of formulation and processing variables on the characteristics of tolmetin microspheres prepared by double emulsion solvent diffusion method.

Authors:  M Jelvehgari; A Nokhodchi; M Rezapour; H Valizadeh
Journal:  Indian J Pharm Sci       Date:  2010-01       Impact factor: 0.975

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.